Psychotropic medications are essential in the treatment of mental illness. Unfortunately, these medications are associated with side effects that may reduce adherence to treatment and quality of life. Therefore, systematic screening for side effects is fundamental to optimize treatment with psychotropic medications. Self-report of side effects is a practical alternative to time-consuming clinical assessments. We developed the Aarhus Side effect Assessment Questionnaire (ASAQ) in an attempt to strike the balance between extensive coverage of side effects and reasonable application time.
Aim:
The aim of the study was to validate the ASAQ using the clinician-rated Udvalg for Kliniske Undersøgelser (UKU) Side Effect Scale as gold standard reference.
Methods:
A total of 122 inpatients and outpatients—mainly with psychotic (39%) and affective disorders (43%)—receiving treatment with psychotropic medication completed the ASAQ and the World Health Organization–Five Well-Being Index (WHO-5) and were subsequently rated on the UKU by trained raters.
Results:
Using the UKU as the gold standard reference, the ASAQ demonstrated sensitivity values >75% for 77% of its 30 items (ranging from 37% for cutaneous disturbances to 98% for increased sweating) and specificity values >75% for 47% of its 30 items (ranging from 28% for reduced sleep to 98% for micturition disturbances). While 17% of the participants considered discontinuing their medication, 24% had recently refrained from taking their medication as prescribed. A negative correlation was found between the ASAQ and the WHO-5 and total scores (Pearson’s correlation coefficient = –0.44).
Conclusions:
The self-reported ASAQ seems to be a sensitive tool for detecting side effects of psychotropic medications.
Ascher-SvanumHZhuBFariesDE, et al. (2009) Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes2: 6.
2.
AshoorianDDavidsonRRockD, et al. (2014) A review of self-report medication side effect questionnaires for mental health patients. Psychiatry Research219(3): 664–673.
3.
BarnesTRBhattiSFAdroerR, et al. (2015) Screening for the metabolic side effects of antipsychotic medication: Findings of a 6-year quality improvement programme in the UK. BMJ Open5(10): e007633.
4.
BechPAhlforsUGDenckerSJ, et al. (1986) UKU’s Bivirkningsskala Skala Til Registering af Uønskede Virkninger af Psykofarmaka. Nordisk psykiatrisk tidsskrift / Nordic Journal of Psychiatry40(2): 147–157.
5.
BobesJGarcia-PortillaMPBascaranMT, et al. (2007) Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience9(2): 215–226.
6.
BockCBukhJDVinbergM, et al. (2009) Validity of the diagnosis of a single depressive episode in a case register. Clinical Practice and Epidemiology in Mental Health5: 4.
7.
ByerlyMJNakoneznyPAFisherR, et al. (2006) An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research81(2–3): 311–316.
8.
ChenKPLungFW (2017) Reliability and validity of the short version of Udvalg for Kliniske Undersogelser in antipsychotic treatment. Psychiatric Quarterly88(4): 787–796.
9.
CorrellCUKishimotoTNielsenJ, et al. (2011) Quantifying clinical relevance in the treatment of schizophrenia. Clinical Therapeutics33(12): B16–B39.
10.
DayJCWoodGDeweyM, et al. (1995) A self-rating scale for measuring neuroleptic side-effects: Validation in a group of schizophrenic patients. British Journal of Psychiatry166(5): 650–653.
11.
DibonaventuraMGabrielSDupclayL, et al. (2012) A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry12: 20.
12.
Every-PalmerSNewton-HowesGClarkeMJ (2017) Pharmacological treatment for antipsychotic-related constipation. Cochrane Database of Systematic Reviews1(1): CD011128.
13.
ForsmanJTaipaleHMastermanT, et al. (2019) Adherence to psychotropic medication in completed suicide in Sweden 2006-2013: A forensic-toxicological matched case-control study. European Journal of Clinical Pharmacology75(10): 1421–1430.
14.
HuhnMNikolakopoulouASchneider-ThomaJ, et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet394(10202): 939–951.
15.
JordanSKnightJPointonD (2004) Monitoring adverse drug reactions: Scales, profiles, and checklists. International Nursing Review51(4): 208–221.
16.
KessingL (1998) Validity of diagnoses and other clinical register data in patients with affective disorder. European Psychiatry13(8): 392–398.
17.
KjellgrenKIAhlnerJDahlöfB, et al. (1998) Patients’ and physicians’ assessment of risks associated with hypertension and benefits from treatment. Journal of Cardiovascular Risk5(3): 161–166.
18.
Köhler-ForsbergOGasseCHieronymusF, et al. (2020) Pre-diagnostic and post-diagnostic psychopharmacological treatment of 16 288 patients with bipolar disorder. Bipolar Disorder. Epub ahead of print 11 July. DOI: 10.1111/bdi.12976.
19.
LambertTJCockNAlcockSJ, et al. (2003) Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology18(5): 405–411.
20.
LangKMeyersJLKornJR, et al. (2010) Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatric Services61(12): 1239–1247.
21.
LarsenEBGerlachJ (1996) Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatrica Scandinavica93(5): 381–388.
22.
LeuchtSTardyMKomossaK, et al. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet379(9831): 2063–2071.
23.
LindströmELewanderTMalmU, et al. (2011) Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordisk psykiatrisk tidsskrift / Nordic Journal of Psychiatry55(Suppl. 44): 5–69.
24.
LingjaerdeOAhlforsUGBechP, et al. (1987) The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica. Supplementum334: 1–100.
25.
LongdenEReadJ (2016) Assessing and reporting the adverse effects of antipsychotic medication: A systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clinical Neuropharmacology39(1): 29–39.
26.
MitchellAJDelaffonVVancampfortD, et al. (2012) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine42(1): 125–147.
27.
MojtabaiRCorey-LislePKIpEH, et al. (2012) The Patient Assessment Questionnaire: Initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatry Research200(2–3): 857–866.
28.
MorratoEHNewcomerJWKamatS, et al. (2009) Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care32(6): 1037–1042.
29.
Nevarez-FloresAGSandersonKBreslinM, et al. (2019) Systematic review of global functioning and quality of life in people with psychotic disorders. Epidemiology and Psychiatric Sciences28(1): 31–44.
30.
NielsenJle QuachPEmborgC, et al. (2010) 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatrica Scandinavica122(5): 356–366.
31.
RosenbergKPBleibergKLKoscisJ, et al. (2003) A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: Impact on compliance. Journal of Sex & Marital Therapy29(4): 289–296.
32.
SartoriusN (2014) Patient-reported outcomes in psychiatry. Dialogues in Clinical Neuroscience16(2): 123–124.
33.
Schouby BockMNørgaard Van AchterODinesD, et al. (2020) Clinical validation of the self-reported Glasgow Antipsychotic Side-Effect Scale using the clinician-rated UKU Side-Effect Scale as gold standard reference. Journal of Psychopharmacology34: 820–828.
34.
SimpsonGMAngusJW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. Supplementum212: 11–19.
35.
Staehr JohansenK (1998) The Use of Well-Being Measures in Primary Health Care—The DepCare Project. Geneva: World Health Organization, Regional Office for Europe.
36.
StomskiNJMorrisonPMeyerA (2016) Antipsychotic medication side effect assessment tools: A systematic review. Australian and New Zealand Journal of Psychiatry50(5): 399–409.
37.
ToppCWOstergaardSDSondergaardS, et al. (2015) The WHO-5 Well-Being Index: A systematic review of the literature. Psychotherapy and Psychosomatics84(3): 167–176.
38.
UcokAIncesuCAkerT, et al. (2008) Do psychiatrists examine sexual dysfunction in schizophrenia patients?Journal of Sexual Medicine5(8): 2000–2001.
39.
UggerbyPØstergaardSDRøgeR, et al. (2013) The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Danish Medical Journal Online60(2): A4578.
40.
UherRFarmerAHenigsbergN, et al. (2009) Adverse reactions to antidepressants. British Journal of Psychiatry195(3): 202–210.
41.
van StrienAMKeijsersCJDerijksHJ, et al. (2015) Rating scales to measure side effects of antipsychotic medication: A systematic review. Journal of Psychopharmacology29(8): 857–866.
42.
WaddellLTaylorM (2008) A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. Journal of Psychopharmacology22(3): 238–243.
43.
WHO (1993) The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research. Geneva: WHO.
WoltersHAKnegteringRWiersmaD, et al. (2006) Evaluation of the subjects’ response to antipsychotics questionnaire. International Clinical Psychopharmacology21(1): 63–69.
46.
ZoharJStahlSMollerHJ, et al. (2015) A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology25(12): 2318–2325.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
